Valued Wealth Advisors LLC Purchases 265 Shares of Bristol-Myers Squibb (NYSE:BMY)

Valued Wealth Advisors LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 44.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 861 shares of the biopharmaceutical company’s stock after purchasing an additional 265 shares during the quarter. Valued Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $49,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. McLean Asset Management Corp increased its stake in Bristol-Myers Squibb by 3.3% in the 4th quarter. McLean Asset Management Corp now owns 6,662 shares of the biopharmaceutical company’s stock worth $377,000 after acquiring an additional 212 shares during the last quarter. Cornerstone Wealth Group LLC increased its position in shares of Bristol-Myers Squibb by 6.8% in the fourth quarter. Cornerstone Wealth Group LLC now owns 14,109 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 903 shares during the last quarter. KBC Group NV raised its stake in Bristol-Myers Squibb by 18.4% in the fourth quarter. KBC Group NV now owns 4,054,868 shares of the biopharmaceutical company’s stock valued at $229,343,000 after purchasing an additional 628,908 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $312,000. Finally, Blue Trust Inc. grew its stake in Bristol-Myers Squibb by 34.4% in the 4th quarter. Blue Trust Inc. now owns 34,273 shares of the biopharmaceutical company’s stock worth $1,773,000 after buying an additional 8,772 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP Samit Hirawat acquired 1,830 shares of the stock in a transaction on Friday, November 1st. The stock was acquired at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This represents a 3.04 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.9 %

NYSE BMY opened at $59.68 on Monday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The stock has a market capitalization of $121.05 billion, a PE ratio of -16.63, a PEG ratio of 2.02 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The business’s 50-day moving average is $57.47 and its 200 day moving average is $52.71.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company earned $2.00 EPS. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.16%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BMY shares. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Citigroup upped their price objective on Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $56.27.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.